| Species |
Human |
| Protein Construction |
Fc gamma RIIIA/CD16a (V176) Domain 2 (Gly107-Thr189)
Accession # AAH17865 |
mFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
35.29 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from a 0.22 μm filtered solution in PBS, (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of Fc gamma RIIIA/CD16a (V176) Domain 2 mFc Chimera, Human is greater than 95% as determined by SEC-HPLC.
Fc gamma RIIIA/CD16a (V176) Domain 2 mFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
| Target Background |
Human Fc gamma RIIIA/CD16a Protein is a receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis. |
| Synonyms |
Fc gamma RIIIA; FCGR3; FCGR3A; FCGRIII; FcgRIIIA; FcR-10; CD16A; FCG3; IGFR3; FcRIIIa; FcRIII; CD16; IMD20 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
